- Home
- MNMD vs JMIA Comparison
MNMD vs JMIA Comparison
Compare MNMD & JMIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNMD
- JMIA
- Stock Information
- Founded
- MNMD 2019
- JMIA 2012
- Country
- MNMD United States
- JMIA Germany
- Employees
- MNMD N/A
- JMIA N/A
- Industry
- MNMD Pharmaceuticals and Biotechnology
- JMIA Catalog/Specialty Distribution
- Sector
- MNMD Health Care
- JMIA Consumer Discretionary
- Exchange
- MNMD Nasdaq
- JMIA Nasdaq
- Market Cap
- MNMD 509.2M
- JMIA 412.7M
- IPO Year
- MNMD N/A
- JMIA 2019
- Fundamental
- Price
- MNMD $7.17
- JMIA $4.43
- Analyst Decision
- MNMD Strong Buy
- JMIA Buy
- Analyst Count
- MNMD 7
- JMIA 2
- Target Price
- MNMD $26.29
- JMIA $7.88
- AVG Volume (30 Days)
- MNMD 1.2M
- JMIA 3.9M
- Earning Date
- MNMD 08-12-2025
- JMIA 08-05-2025
- Dividend Yield
- MNMD N/A
- JMIA N/A
- EPS Growth
- MNMD N/A
- JMIA N/A
- EPS
- MNMD N/A
- JMIA N/A
- Revenue
- MNMD N/A
- JMIA $154,854,000.00
- Revenue This Year
- MNMD N/A
- JMIA $10.62
- Revenue Next Year
- MNMD N/A
- JMIA $7.08
- P/E Ratio
- MNMD N/A
- JMIA N/A
- Revenue Growth
- MNMD N/A
- JMIA N/A
- 52 Week Low
- MNMD $4.70
- JMIA $1.60
- 52 Week High
- MNMD $10.44
- JMIA $15.04
- Technical
- Relative Strength Index (RSI)
- MNMD 52.28
- JMIA 69.30
- Support Level
- MNMD $6.40
- JMIA $3.16
- Resistance Level
- MNMD $7.20
- JMIA $4.71
- Average True Range (ATR)
- MNMD 0.43
- JMIA 0.30
- MACD
- MNMD -0.03
- JMIA 0.12
- Stochastic Oscillator
- MNMD 76.03
- JMIA 83.43
About MNMD Mind Medicine (MindMed) Inc.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).
About JMIA Jumia Technologies AG each representing two
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates majority of its revenue from the West Africa segment.